Daphne Koller is the CEO and founder of Insitro, a machine learning-driven drug discovery and development company that recently made news for its identification of a novel drug target for ALS and its collaboration with Eli Lilly to license Lilly’s biochemical delivery systems. Prior to founding Insitro, Daphne was the co-founder, co-CEO, and president of the online education platform Coursera. Noubar Afeyan is the founder and CEO of Flagship Pioneering, which creates biotechnology companies focused on transforming human health and […]

DANIEL CARPENTER: Thanks for having me.  SULLIVAN: Dan, before we dissect policy, let’s rewind the tape to your origin story. Can you take us to the moment that you first became fascinated with regulators rather than, say, politicians? Was there a spark that pulled you toward the FDA story?  CARPENTER: At one point during graduate school, I was studying a combination of American politics and political theory, and I did a summer interning at the Department of Housing and Urban Development. And I began to think, why […]

ALTA CHARO: It’s my pleasure. Thanks for having me. SULLIVAN: Alta, I’d love to begin by stepping back in time a bit before you became a leading figure in bioethics and legal policy. You’ve shared that your interest in science was really inspired by your brothers’ interest in the topic and that your upbringing really helped shape your perseverance and resilience. Can you talk to us about what put you on the path to law and policy? CHARO: Well, I […]

In our ever-evolving journey to enhance healthcare through  

[MUSIC ENDS]   For our introductory episode, I’m pleased to welcome Amanda Craig Deckard from Microsoft to discuss the company’s efforts to learn about testing in other sectors.   Amanda is senior director of public policy in the Office of Responsible AI, where she leads a team that works closely with engineers, researchers, and policy experts to help ensure AI is being developed and used responsibly. Their insights shape Microsoft’s contribution to public policy discussions on laws, norms, and standards for AI.   […]

As generative AI becomes more capable and widely deployed, familiar questions from the governance of other transformative technologies have resurfaced. Which opportunities, capabilities, risks, and impacts should be evaluated? Who should conduct evaluations, and at what stages of the technology lifecycle? What tests or measurements should be used? And how can we know if the results are reliable?   Recent research and reports from Microsoft (opens in new tab), the

We are excited to share our first big milestone in solving a grand challenge that has hampered the predictive power of computational chemistry, biochemistry, and materials science for decades. By using a scalable deep-learning approach and generating an unprecedented quantity of diverse,  

Artificial intelligence is advancing across a wide range of fields, with one of the most important developments being its growing capacity for reasoning. This capability  

The book passage I read at the top is from “Chapter 10: The Big Black Bag.”  In imagining AI in medicine, Carey, Zak, and I included in our book two fictional accounts. In the first, a medical resident consults GPT-4 on her personal phone as the patient in front of her crashes. Within seconds, it offers an alternate response based on recent literature. In the second account, a 90-year-old woman with several chronic conditions is living independently and receiving near-constant […]

One of the key use cases for generative AI involves answering questions over private datasets, with retrieval-augmented generation (RAG) as the go-to framework. As new RAG techniques emerge, there’s a growing need to benchmark their performance across diverse datasets and metrics.  To meet this need, we’re introducing BenchmarkQED, a new suite of tools that automates RAG benchmarking at scale, available on